Novel mechanism underlying fibrinogen biogenesis in the endoplasmic reticulum
Novel mechanism underlying fibrinogen biogenesis in the endoplasmic reticulum
批准号:
10681373
负责人:
Shengyi Sun
金额:
$5.76万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-15 至 2024-06-30
关键词:
AdultAgeAge MonthsAutophagocytosisBiochemicalBiogenesisBiological AssayBlood coagulationCoagulation ProcessDataDiseaseDominant-Negative MutationEndoplasmic ReticulumEventExhibitsFGF21 geneFibrinogenGrowthHemorrhageHepaticHepatocyteHomeostasisHumanImaging TechniquesInclusion BodiesLabelLiverMissense MutationMolecularMolecular ChaperonesMolecular ConformationMusPathogenesisPathogenicityPathologicPatientsProteinsQuality ControlRoleTestingTherapeuticTransmission Electron Microscopyautosomecell typeclinically relevantdisulfide bondfibroblast growth factor 21human diseaseinsightliver injurymisfolded proteinmutantnovelpreventprotein complexprotein misfoldingproteostasisrecruitresponseubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
A large number of diseases are now recognized as ‘conformational diseases’, caused by protein misfolding and subsequent aggregation. One example is hepatic fibrinogen storage disease (HFSD), where the underlying cause is the endoplasmic reticulum (ER) retention and aggregation of fibrinogen mutants, leading to liver damage, hypofibrinogenemia, and excessive bleeding. However, the molecular events underlying the biogenesis and quality control of, both wildtype and mutant fibrinogen, in the ER remain unknown. In the preliminary data of this application, we serendipitously found that the biogenesis of fibrinogen is regulated by the Sel1L-Hrd1 protein complex of the principal ER quality-control machinery, ER-associated degradation (ERAD). Sel1L-Hrd1 ERAD represents the most evolutionarily conserved branch of ERAD and targets misfolded ER proteins for cytosolic proteasomal degradation. Hepatocyte-specific Sel1L-deficient mice exhibit fibrinogen-containing inclusions in the ER of hepatocytes, hepatic damage and hypofibrinogenemia, resembling human patients with HFSD. Indeed, both wildtype and disease-causing mutants of fibrinogens are degraded by Sel1L-Hrd1 ERAD. These data point to a critical role of hepatocyte Sel1L-Hrd1 ERAD in fibrinogen biogenesis and live homeostasis. Hence, the overarching hypothesis of this application is that Sel1L-Hrd1 ERAD is a critical regulatory mechanism for fibrinogen biogenesis, coagulation and liver homeostasis by targeting misfolded, either wildtype or mutant, fibrinogen proteins for proteasomal degradation. This action of ERAD towards fibrinogen prevents the formation of toxic fibrinogen inclusions and aggregates in the liver. We will accomplish two Aims: (1) Demonstrate the significance and molecular mechanism of hepatic Sel1L-Hrd1 ERAD in coagulation and fibrinogen biogenesis; and (2) Delineate the pathological importance of Sel1L-Hrd1 ERAD in HFSD. Completion of these studies will not only delineate the significance and molecular mechanism underlying the ERAD function in early biogenesis of fibrinogen, but also have broader impact on the mechanism and therapeutical strategy for other conformational diseases associated with protein misfolding.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel mechanism underlying fibrinogen biogenesis in the endoplasmic reticulum
-
批准号:10418307
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2022
-
负责人:Shengyi Sun
-
依托单位:
Novel role of endoplasmic reticulum-associated degradation in iron metabolism
-
批准号:10364117
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2021
-
负责人:Shengyi Sun
-
依托单位:
Novel role of endoplasmic reticulum-associated degradation in iron metabolism
-
批准号:10532368
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2021
-
负责人:Shengyi Sun
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: